FREEDOM OF INFORMATION SUMMARY
ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-719

SIMPLERA™
(flорfenicol, тербинафин, мометазон фуроат)
Solution
Dogs

SIMPLERA™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

Sponsored by:
Vetoquinol USA, Inc.
Table of Contents

I. GENERAL INFORMATION .................................................................................. 3
II. BIOEQUIVALENCE ......................................................................................... 4
III. HUMAN FOOD SAFETY .................................................................................. 4
IV. USER SAFETY .................................................................................................. 4
V. AGENCY CONCLUSIONS .................................................................................. 5
I. GENERAL INFORMATION

A. File Number
   ANADA 200-719

B. Sponsor
   Vetoquinol USA, Inc.
   4250 N. Sylvania Ave.
   Fort Worth, TX  76137
   
   Drug Labeler Code: 017030

C. Proprietary Name
   SIMPLERA™

D. Drug Product Established Name
   florfenicol, terbinafine, mometasone furoate

E. Pharmacological Category
   Antibacterial, antifungal, and anti-inflammatory

F. Dosage Form
   Solution

G. Amount of Active Ingredient
   16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride) and 2.2 mg/mL mometasone furoate

H. How Supplied
   Supplied in a single-use dropperette in a blister. Each dropperette contains one 1 mL dose. Available in cartons of ten dropperettes.

I. Dispensing Status
   Prescription (Rx)

J. Dosage Regimen
   Administer one dose (1 dropperette) per affected ear.

K. Route of Administration
   Otic

L. Species/Class
   Dogs
M. Indications

SIMPLERA™ is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

N. Reference Listed New Animal Drug (RLNAD)

CLARO™; florfenicol, terbinafine, mometasone furoate; NADA 141-440; Elanco US Inc.

II. BIOEQUIVALENCE

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food-producing animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform in vivo bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Vetoquinol USA, Inc., was granted a biowaiver for the generic product SIMPLERA™ (florfenicol, terbinafine, mometasone furoate) otic solution. The generic drug product is a solution, contains the same active ingredients in the same concentrations and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is CLARO™ (florfenicol, terbinafine, mometasone furoate) otic solution, sponsored by Elanco US Inc., under NADA 141-440, and was approved for use in dogs on September 20, 2015.

III. HUMAN FOOD SAFETY

This drug is intended for use in dogs. Because this new animal drug is not intended for use in food-producing animals, CVM did not require data pertaining to drug residues in food (i.e., human food safety) for approval of this ANADA.

IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to SIMPLERA™:

Wear eye protection when administering SIMPLERA™.

Splatter may occur if the dog shakes its head following administration. Persons near the dog during administration should also take steps to avoid ocular exposure.

SIMPLERA™ may cause eye injury and irritation.
If contact with eyes occurs, flush copiously with water for at least 15 minutes. If irritation persists, contact a physician.

Humans with known hypersensitivity to any of the active ingredients in SIMPLERA™ should not handle this product.

Not for use in humans. Keep this and all drugs out of reach of children. Avoid skin contact. In case of accidental ingestion by humans, contact a physician immediately.

**Wear eye protection when administering SIMPLERA™ and restrain the dog** to minimize post application head shaking. Reducing the potential for splatter of product will help prevent accidental eye exposure in people and dogs and help to prevent ocular injury.

V. **AGENCY CONCLUSIONS**

The data submitted in support of this ANADA satisfy the requirements of section 512(c)(2) of the FD&C Act. The data demonstrate that SIMPLERA™, when used according to the label, is safe and effective for the indications listed in Section I.M. above.